Dry Eye Disease (DED)
Dry eye disease is a common, chronic condition of the ocular surface in which the tear film loses its stability and the eye can no longer protect and lubricate itself properly. It is far from a minor complaint: studies assessing both signs and symptoms find that roughly one in three adults carry a diagnosis, and around one in five children, yet it remains widely underdiagnosed and undertreated.
A symptomatic disease
The leading international consensus, the TFOS DEWS III Management and Therapy Report (TFOS DEWS III, 2025, American Journal of Ophthalmology), defines dry eye as a symptomatic disease and a subset of ocular surface disease. Symptoms sit at the front of the definition, which means a patient with signs but no symptoms is not, by that definition, a dry eye patient. DEWS III also recognises that disease is individual: the etiological factors that drive it differ from person to person, and most patients carry more than one.
Symptoms
Common symptoms include burning, a gritty or foreign-body sensation, paradoxical watering, eye fatigue, light sensitivity and fluctuating vision. For people with severe disease, the quality-of-life impact in utility studies sits alongside conditions such as angina or dialysis.
What drives it
DEWS III organises dry eye around drivers in three groups: tear film deficiencies, eyelid anomalies such as meibomian gland dysfunction, and ocular surface abnormalities. The older split into evaporative versus aqueous-deficient disease has given way to this spectrum, because only around five percent of patients are purely aqueous-deficient.
How it is diagnosed
Diagnosis follows a short, repeatable pathway: screen with the OSDI-6, confirm with a single sign such as a non-invasive tear breakup time under ten seconds, and assess ocular surface staining, which is the test that cannot be skipped.
How it is treated
Treatment ranges from artificial tears and lid hygiene to in-office light-based therapy. LM™ LLLT photobiomodulation, delivered on eye-light®, is recognised in DEWS III as beneficial across all three driver groups, making it well suited to the multi-driver reality of most patients. For the full picture of options, see the dry eye treatment overview, and for patients, the dry eye guide.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.